Literature DB >> 21364534

Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL.

Prediman K Shah1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21364534     DOI： 10.1038/nrcardio.2011.37

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

Review 1.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II.

Authors:  P K Shah; S Kaul; J Nilsson; B Cercek
Journal:  Circulation       Date:  2001-11-13       Impact factor: 29.690

Review 2.  Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I.

Authors:  P K Shah; S Kaul; J Nilsson; B Cercek
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

Review 3.  Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.

Authors:  Prediman K Shah
Journal:  Curr Opin Cardiol       Date:  2010-11       Impact factor: 2.161

Review 4.  The protein cargo of HDL: implications for vascular wall biology and therapeutics.

Authors:  Jay W Heinecke
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

Review 5.  The yin and yang of cholesteryl ester transfer protein in cardiovascular disease.

Authors:  Prediman K Shah
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

6.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

7.  Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.

Authors:  Stephen J Nicholls; Allan Gordon; Jan Johansson; Kathy Wolski; Christie M Ballantyne; John J P Kastelein; Allen Taylor; Marilyn Borgman; Steven E Nissen
Journal:  J Am Coll Cardiol       Date:  2011-01-20       Impact factor: 24.094

8.  RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.

Authors:  Dana Bailey; Ravi Jahagirdar; Allan Gordon; Anouar Hafiane; Steven Campbell; Safia Chatur; Gregory S Wagner; Henrik C Hansen; Fabrizio S Chiacchia; Jan Johansson; Larbi Krimbou; Norman C W Wong; Jacques Genest
Journal:  J Am Coll Cardiol       Date:  2010-06-08       Impact factor: 24.094

9.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

10.  High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.

Authors:  Wim A van der Steeg; Ingar Holme; S Matthijs Boekholdt; Mogens Lytken Larsen; Christina Lindahl; Erik S G Stroes; Matti J Tikkanen; Nicholas J Wareham; Ole Faergeman; Anders G Olsson; Terje R Pedersen; Kay-Tee Khaw; John J P Kastelein
Journal:  J Am Coll Cardiol       Date:  2008-02-12       Impact factor: 24.094
  10 in total
  6 in total

Review 1.  Role of the gut in lipid homeostasis.

Authors:  Nada A Abumrad; Nicholas O Davidson
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

2.  Liver X receptor agonist modulation of cholesterol efflux in mice with intestine-specific deletion of microsomal triglyceride transfer protein.

Authors:  Yan Xie; Susan Kennedy; Rohini Sidhu; Jianyang Luo; Daniel S Ory; Nicholas O Davidson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-10       Impact factor: 8.311

3.  Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus.

Authors:  Hyung Joon Joo; Sang-A Cho; Soon Jun Hong; Seung-Ho Hur; Jang-Ho Bae; Dong-Ju Choi; Young-Keun Ahn; Jong-Seon Park; Rak-Kyeong Choi; Donghoon Choi; Joon-Hong Kim; Kyoo-Rok Han; Hun-Sik Park; So-Yeon Choi; Jung-Han Yoon; Hyeon-Cheol Kwon; Seung-Woon Rha; Kyung-Kuk Hwang; Kyung-Tae Jung; Seok-Kyu Oh; Jae-Hwan Lee; Eun-Seok Shin; Kee-Sik Kim; Hyo-Soo Kim; Do-Sun Lim
Journal:  Lipids Health Dis       Date:  2016-11-18       Impact factor: 3.876

4.  HDL, Atherosclerosis, and Emerging Therapies.

Authors:  Anouar Hafiane; Jacques Genest
Journal:  Cholesterol       Date:  2013-05-28

Review 5.  Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL.

Authors:  Peiqiu Cao; Haitao Pan; Tiancun Xiao; Ting Zhou; Jiao Guo; Zhengquan Su
Journal:  Int J Mol Sci       Date:  2015-07-28       Impact factor: 5.923

6.  Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma.

Authors:  Lindsay M Scheetz; Minzhi Yu; Dan Li; María G Castro; James J Moon; Anna Schwendeman
Journal:  Int J Mol Sci       Date:  2020-03-05       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.